-
Supplement: Novel Cancer Immunotherapy Combos
Researchers Contextualize Immuno-Oncology Mechanisms to Advance Personalized Therapies
-
Playing Catch-Up with Optogenetic Effects
Optogenetically Triggered Processes Needn’t Become Visualization and Mapping Blurs
-
Work on DNA Vaccines Still Has a Way to Go
Best Positioned for Diseases that Require a Rapid Response
-
True CRISPR: A Genetic Genre with Novel Twists
With Multiplexing, Nanodelivery, and Other Advances, CRISPR Reality Outstrips CRISPR Fiction
GEN Editorial and
Scientific Advisory Board
-
Peter Banks, Ph.D.
Scientific Director, BiotTek Instruments -
Roslyn (Brandon) Hendriks, D.V.M.
Managing Partner at C-Suite Corporate, The University of Queensland -
Robert Clarke, Ph.D.
President & CEO, Pulmatrix -
Pete Gagnon
Chief Scientific Officer, BIA Separations -
Uwe Gottschalk, Ph.D.
Chief Scientific Officer, Lonza -
Harry E. Gruber, M.D.
CEO, Tocagen: Jin Seok Hur, Ph.D., Technology Director, Novasep -
James Inglese, Ph.D.
Investigator at National Center for Advancing Translational Sciences -
Guenter Jagschies
Senior Director, GE Healthcare Life Sciences -
Peter Johnson, M.D.
Principal, MedisurgePI -
Anis H. Khimani, Ph.D.
Head of Strategy and Marketing, Research Reagent Solutions, PerkinElmer -
Mikael Kubista, Ph.D.
CEO and Founder, TATAA Biocenter -
Peter Levison
Senior Marketing Director, Downstream Processing, Pall Life Sciences -
Jan Lichtenberg, Ph.D.
CEO and Co-Founder, InSphero -
Miodrag MIcic, Sc.D., Ph.D.
Professor and Department Chairman, Cerritos College -
Eric Schadt, Ph.D.
Founder and CEO, Sema4 -
Zhiwei Song, Ph.D.
Scientist, National University of Singapore -
Sumio Sugano, M.D., Ph.D.
Professor, Medical Genomics, University of Tokyo -
John Talley, Ph.D.
Medicinal Chemist, Euclises Pharmaceuticals -
Bin Wang, Ph.D., Professor
Principal Investigator, Fudan University Medical College -
Daniel Wang, Ph.D.
Institute Professor of Chemical Engineering, MIT
